<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624180</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00070892</org_study_id>
    <secondary_id>1R01HL125059</secondary_id>
    <nct_id>NCT02624180</nct_id>
  </id_info>
  <brief_title>Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV</brief_title>
  <official_title>Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying whether an anti-inflammatory intervention improves impaired&#xD;
      coronary endothelial function (CEF) in HIV+ people with no clinical coronary artery disease&#xD;
      (CAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Survival in people with HIV has significantly improved with the use of antiretroviral therapy&#xD;
      (ART) but HIV+ people now experience an increasing burden of chronic diseases, including&#xD;
      coronary atherosclerosis and coronary artery disease (CAD). HIV patients manifest an&#xD;
      increased risk of CAD and its consequences possibly due to interplay of inflammation with&#xD;
      traditional risk factors (smoking, high cholesterol, and poor diet), some of the latter&#xD;
      accentuated by ART.&#xD;
&#xD;
      What the investigators are studying in this program is the function of the coronary arteries&#xD;
      and in particular the inner lining of the arteries called the endothelium in patients with&#xD;
      HIV. The endothelium has several important functions; one of them is that under conditions of&#xD;
      stress it releases a substance called nitric oxide which increases the size of the artery and&#xD;
      increases blood flow. When it is not functioning normally the artery does not increase as&#xD;
      much and blood flow does not increase during stress.&#xD;
&#xD;
      The investigators study coronary artery function with magnetic resonance imaging, or MRI. MRI&#xD;
      is a method of obtaining images of what is happening inside the body. MRI does not involve&#xD;
      radiation, x-ray, or injection of contrast. The investigators can measure flow in the artery&#xD;
      and the dimension of the artery at rest and with a handgrip stress and learn the extent to&#xD;
      which the artery dilates and flow increases with the stress. The investigators believe that&#xD;
      inflammation can interfere with normal function and that by decreasing inflammation abnormal&#xD;
      endothelial function may be improved.&#xD;
&#xD;
      Colchicine is an anti-inflammatory agent approved by the Food and Drug Administration (FDA)&#xD;
      to treat arthritis and some other conditions. This drug is not approved for use to suppress&#xD;
      inflammation in patients with coronary artery disease and improve coronary artery endothelial&#xD;
      function. The FDA is allowing the use of colchicine or a placebo in this research study.&#xD;
&#xD;
      This study will involve 24 weeks of colchicine or placebo and 3 Magnetic Resonance Imaging&#xD;
      (MRI) scans of the heart and other study procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks</measure>
    <time_frame>Difference between measurements at baseline compared to measurement at 8 weeks</time_frame>
    <description>Percent change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stress at 8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary Endothelial Function at 24 Weeks;</measure>
    <time_frame>At 24 weeks.</time_frame>
    <description>Change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stress at 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coronary Artery Cross-sectional Area (CSA) at 8 Weeks</measure>
    <time_frame>Difference between measurements at baseline compared to measurement at 8 weeks</time_frame>
    <description>Change in CSA as measured by the difference between CSA at rest and under IHE stress at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coronary Artery Cross-sectional Area (CSA) at 24 Weeks</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Change in CSA as measured by the difference between CSA at rest and under IHE stress at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive Protein (hsCRP) at 8 Weeks.</measure>
    <time_frame>At 8 weeks.</time_frame>
    <description>High-sensitivity C-reactive protein (hsCRP) at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brachial Flow Mediated Dilatation (FMD) at 8 Weeks.</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Brachial flow mediated dilatation (FMD) at 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6) at 8 Weeks</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Interleukin-6 (IL-6) at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive Protein (hsCRP) at 24 Weeks</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>High-sensitivity C-reactive Protein (hsCRP) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brachial Flow Mediated Dilatation (FMD) at 24 Weeks.</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Brachial Flow Mediated Dilatation (FMD) at 24 Weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.6 mg daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for colchicine 1 tablet by mouth daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
    <arm_group_label>Colchicine</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A substance containing no medication</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of either gender who are 21 years of age (no upper age limit), HIV positive&#xD;
             and taking stable ART (no change in ART regimen in last 3 months),&#xD;
&#xD;
          -  HIV viral load &lt;100 copies/mL (plasma HIV RNA concentration),&#xD;
&#xD;
          -  Abnormal CEF at baseline (&lt;7ml/min change in CBF during IHE as compared to resting&#xD;
             value).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to understand the risks, benefits, and alternatives of participation&#xD;
             and give meaningful consent,&#xD;
&#xD;
          -  Patients with contraindications to MRI such as implanted metallic objects&#xD;
             (pre-existing cardiac pacemakers, cerebral clips) or indwelling metallic projectiles,&#xD;
&#xD;
          -  History of clinical CAD, including acute coronary syndrome, myocardial infarction or&#xD;
             revascularization,&#xD;
&#xD;
          -  Resting ECG with evidence of Q wave myocardial infarction,&#xD;
&#xD;
          -  Pregnant women,&#xD;
&#xD;
          -  Recent history, within the past 3 months, of cocaine or heroin use,&#xD;
&#xD;
          -  Moderate or greater renal impairment (estimated glomerular filtration rate &lt;45ml/min),&#xD;
&#xD;
          -  Moderate-severe hepatic disease (elevation in hepatic transaminases &gt;3x upper limit of&#xD;
             normal),&#xD;
&#xD;
          -  Leukopenia (&lt;3000/mm3) or thrombocytopenia (&lt;100,000/mm3),&#xD;
&#xD;
          -  CD4&lt;200 cell/mm3,&#xD;
&#xD;
          -  Chronic inflammatory condition such as lupus or rheumatoid arthritis, ulcerative&#xD;
             colitis or Crohn's disease,&#xD;
&#xD;
          -  Requirement for, or intolerance to, colchicine,&#xD;
&#xD;
          -  Women of childbearing potential (even if using oral contraceptive agents) or intention&#xD;
             to breastfeed,&#xD;
&#xD;
          -  Chronic, continuous use of oral or IV steroid therapy or other immunosuppressive or&#xD;
             biologic response modifiers or anti-inflammatory agents (chronic NSAIDs or&#xD;
             acetylsalicylic acid (ASA) &gt;81mg daily),&#xD;
&#xD;
          -  History of chronic pericardial effusion, pleural effusion, ascites or peripheral&#xD;
             neuropathy manifested by both signs and symptoms,&#xD;
&#xD;
          -  Taking protease inhibitors (PI), cobicistat, or CYP3A4 inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007 Mar 13;115(10):1285-95. Review.</citation>
    <PMID>17353456</PMID>
  </reference>
  <reference>
    <citation>Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003 Oct 1;42(7):1149-60. Review.</citation>
    <PMID>14522472</PMID>
  </reference>
  <reference>
    <citation>Hays AG, Hirsch GA, Kelle S, Gerstenblith G, Weiss RG, Stuber M. Noninvasive visualization of coronary artery endothelial function in healthy subjects and in patients with coronary artery disease. J Am Coll Cardiol. 2010 Nov 9;56(20):1657-65. doi: 10.1016/j.jacc.2010.06.036.</citation>
    <PMID>21050976</PMID>
  </reference>
  <reference>
    <citation>Hays AG, Stuber M, Hirsch GA, Yu J, Schär M, Weiss RG, Gerstenblith G, Kelle S. Non-invasive detection of coronary endothelial response to sequential handgrip exercise in coronary artery disease patients and healthy adults. PLoS One. 2013;8(3):e58047. doi: 10.1371/journal.pone.0058047. Epub 2013 Mar 11.</citation>
    <PMID>23536782</PMID>
  </reference>
  <reference>
    <citation>Hays AG, Kelle S, Hirsch GA, Soleimanifard S, Yu J, Agarwal HK, Gerstenblith G, Schär M, Stuber M, Weiss RG. Regional coronary endothelial function is closely related to local early coronary atherosclerosis in patients with mild coronary artery disease: pilot study. Circ Cardiovasc Imaging. 2012 May 1;5(3):341-8. doi: 10.1161/CIRCIMAGING.111.969691. Epub 2012 Apr 5.</citation>
    <PMID>22492483</PMID>
  </reference>
  <reference>
    <citation>Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027. Epub 2012 Dec 19.</citation>
    <PMID>23265346</PMID>
  </reference>
  <reference>
    <citation>Brown BG, Lee AB, Bolson EL, Dodge HT. Reflex constriction of significant coronary stenosis as a mechanism contributing to ischemic left ventricular dysfunction during isometric exercise. Circulation. 1984 Jul;70(1):18-24.</citation>
    <PMID>6426817</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <results_first_submitted>July 27, 2021</results_first_submitted>
  <results_first_submitted_qc>July 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2021</results_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02624180/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two participants randomized to colchicine withdrew before receiving study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Colchicine</title>
          <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colchicine</title>
          <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.66" lower_limit="45.0" upper_limit="60.7"/>
                    <measurement group_id="B2" value="52.0" lower_limit="45.2" upper_limit="57.4"/>
                    <measurement group_id="B3" value="54.25" lower_limit="45.1" upper_limit="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks</title>
        <description>Percent change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stress at 8 weeks.</description>
        <time_frame>Difference between measurements at baseline compared to measurement at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks</title>
          <description>Percent change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stress at 8 weeks.</description>
          <units>Percent change from rest measurement</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="4.4"/>
                    <measurement group_id="O2" value="13.4" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coronary Endothelial Function at 24 Weeks;</title>
        <description>Change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stress at 24 weeks.</description>
        <time_frame>At 24 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Endothelial Function at 24 Weeks;</title>
          <description>Change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stress at 24 weeks.</description>
          <units>Percent change from rest measurement</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" lower_limit="-11.56" upper_limit="20.35"/>
                    <measurement group_id="O2" value="16.60" lower_limit="-2.04" upper_limit="29.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Coronary Artery Cross-sectional Area (CSA) at 8 Weeks</title>
        <description>Change in CSA as measured by the difference between CSA at rest and under IHE stress at 8 weeks</description>
        <time_frame>Difference between measurements at baseline compared to measurement at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Coronary Artery Cross-sectional Area (CSA) at 8 Weeks</title>
          <description>Change in CSA as measured by the difference between CSA at rest and under IHE stress at 8 weeks</description>
          <units>Percent change from baseline measurement</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-5.75" upper_limit="3.99"/>
                    <measurement group_id="O2" value="1.53" lower_limit="-3.76" upper_limit="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Coronary Artery Cross-sectional Area (CSA) at 24 Weeks</title>
        <description>Change in CSA as measured by the difference between CSA at rest and under IHE stress at 24 weeks</description>
        <time_frame>At 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Coronary Artery Cross-sectional Area (CSA) at 24 Weeks</title>
          <description>Change in CSA as measured by the difference between CSA at rest and under IHE stress at 24 weeks</description>
          <units>Percent change from rest measurement</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" lower_limit="-5.86" upper_limit="6.61"/>
                    <measurement group_id="O2" value="5.04" lower_limit="-1.60" upper_limit="13.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-sensitivity C-reactive Protein (hsCRP) at 8 Weeks.</title>
        <description>High-sensitivity C-reactive protein (hsCRP) at 8 weeks</description>
        <time_frame>At 8 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>High-sensitivity C-reactive Protein (hsCRP) at 8 Weeks.</title>
          <description>High-sensitivity C-reactive protein (hsCRP) at 8 weeks</description>
          <units>mg/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="0.77" upper_limit="4.67"/>
                    <measurement group_id="O2" value="1.26" lower_limit="0.86" upper_limit="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brachial Flow Mediated Dilatation (FMD) at 8 Weeks.</title>
        <description>Brachial flow mediated dilatation (FMD) at 8 weeks.</description>
        <time_frame>At 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Flow Mediated Dilatation (FMD) at 8 Weeks.</title>
          <description>Brachial flow mediated dilatation (FMD) at 8 weeks.</description>
          <units>% brachial artery dilation</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" lower_limit="1.76" upper_limit="6.17"/>
                    <measurement group_id="O2" value="4.12" lower_limit="2.09" upper_limit="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-6 (IL-6) at 8 Weeks</title>
        <description>Interleukin-6 (IL-6) at 8 weeks</description>
        <time_frame>At 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6 (IL-6) at 8 Weeks</title>
          <description>Interleukin-6 (IL-6) at 8 weeks</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.43" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.42" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-sensitivity C-reactive Protein (hsCRP) at 24 Weeks</title>
        <description>High-sensitivity C-reactive Protein (hsCRP) at 24 weeks</description>
        <time_frame>At 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>High-sensitivity C-reactive Protein (hsCRP) at 24 Weeks</title>
          <description>High-sensitivity C-reactive Protein (hsCRP) at 24 weeks</description>
          <units>mg/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="3.20"/>
                    <measurement group_id="O2" value="1.30" lower_limit="0.80" upper_limit="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brachial Flow Mediated Dilatation (FMD) at 24 Weeks.</title>
        <description>Brachial Flow Mediated Dilatation (FMD) at 24 Weeks.</description>
        <time_frame>At 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Flow Mediated Dilatation (FMD) at 24 Weeks.</title>
          <description>Brachial Flow Mediated Dilatation (FMD) at 24 Weeks.</description>
          <units>% brachial artery dilation</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" lower_limit="2.25" upper_limit="7.25"/>
                    <measurement group_id="O2" value="3.46" lower_limit="1.41" upper_limit="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over study enrollment (up to 24 weeks after randomization to study drug)</time_frame>
      <desc>Two participants randomized to colchicine withdrew before receiving study drug so number of participants at risk listed here as 41.</desc>
      <group_list>
        <group group_id="E1">
          <title>Colchicine</title>
          <description>Colchicine 0.6 mg daily by mouth&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo for colchicine 1 tablet by mouth daily&#xD;
Placebo: A substance containing no medication</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Urinary tract infection requiring hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Participant underwent elective carotid endarterectomy during study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased White Blood Cell</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Decreased Hematocrit</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dental pain/infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Aspartate Amino Trans</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Increased Alanine Amino Trans</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Physical Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint/Muscle Soreness/Stiffness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Estimated GFR</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert G. Weiss, MD</name_or_title>
      <organization>Johns Hopkins Hospital</organization>
      <phone>410-955-1703</phone>
      <email>rweiss@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

